Xerox Holdings Corp. reported a 25.7% year-over-year revenue increase to $2.03 billion in Q4 2025, yet fell short of Wall Street expectations. The company's full-year guidance and per-share loss also disappointed analysts, as margin pressures and acquisition integration complexities weigh on its transformation journey.
Dover Corporation topped revenue and profit forecasts for the fourth quarter, fueled by robust order growth in climate tech and retail segments. However, shares dipped as management issued a guarded outlook for the coming year, citing input cost pressures and macroeconomic uncertainty.
Florida-based Seacoast Banking Corporation (SBCF) capped off 2025 with robust loan growth and margin expansion, fueled by its recent acquisition of Villages Bancorporation. Management outlined confident guidance for the coming year, forecasting significant earnings per share growth and improved returns.
The United States has sanctioned Iran's Interior Minister and a prominent businessman, accusing them of human rights abuses and money laundering, as Washington intensifies pressure on Tehran amid ongoing regional tensions.
CNBC's Jim Cramer endorsed Carrier Global Corp. (NYSE:CARR) on his recent show, praising CEO Dave Gitlin's leadership and strategic acquisition. He recommended investors buy the stock for the long term, citing confidence in the company's positioning within the climate solutions sector.
Business Facilities magazine has named North Carolina its 'State of the Year' for business climate and economic development, the state's third such win in six years, following a surge of multi-billion dollar investments from tech and manufacturing giants.
With interest rate uncertainty and global headwinds buffeting markets, income-focused investors are turning to dividend-paying stocks for potential stability. We examine three ASX-listed companies offering yields above 3%, assessing their resilience in the current climate.
As NorthWestern Energy Group (NWE) approaches its quarterly report, a surge in share price has investors questioning whether optimism has outpaced fundamentals. With shares trading above analyst targets, the debate centers on future growth prospects versus current valuation concerns.
Financial expert Suze Orman challenges conventional retirement targets, urging a defensive cash reserve of three to five years' expenses to shield against market volatility.
Amid tightening climate regulations, Southern States LLC launches a new line of high-voltage switching products that replace the potent greenhouse gas SF6 with a readily available blend of carbon dioxide and oxygen, promising a dramatic reduction in environmental impact without compromising grid reliability.
Chicago's downtown office vacancy rate soared to a historic 28.2% at the close of 2025, more than double pre-pandemic levels, as remote work trends and business climate concerns drive a 14th consecutive quarter of record vacancies. Analysts warn of a deepening economic spiral with implications for city services and residents.
Despite a recent earnings miss, Charles Schwab's stock has significantly outpaced the market over the past year. Wall Street maintains a cautiously optimistic stance, with upgraded ratings and bullish price targets pointing to further potential gains.
Micron Technology's stock is under renewed scrutiny as analysts adjust price targets, reflecting a pivotal shift in how the memory chipmaker is perceived amidst evolving AI and data center demand. The reassessment underscores broader market recalibration for semiconductor players.
Lucid Air Grand Touring secures the top spot in a grueling Nordic winter range test, providing a much-needed technical validation for the luxury EV maker amidst a challenging market climate.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
While analyst price targets often paint a rosy picture, a deeper look reveals which recommendations are backed by solid business trends and which may be overly optimistic. We examine one fintech disruptor and one industrial stalwart favored by the Street, alongside a retailer facing significant headwinds.
Security forces are engaged in extensive operations across Balochistan following a devastating wave of coordinated assaults by separatist militants on civilian and government targets over the weekend, which killed nearly 50 people and marked a significant escalation in the long-running conflict.
While analyst price targets often paint a rosy picture, a closer look reveals a more nuanced reality. We examine one favored stock with solid fundamentals and two others where the Street's optimism may be overlooking critical risks.
